Ultragenyx Pharmaceutical Inc
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →
Analyst Sentiment
Ultragenyx appears attractively valued at current levels. With a 155.6% upside to our $67.82 target, the risk-reward profile looks favorable for investors with a 12-month time horizon. Wall Street agrees, with 89% of analysts rating it a Buy.
The 24/7 Factor
5-Year Projection
Prediction History
| Date | Price Target | Stock Price | Rating | Upside |
|---|---|---|---|---|
| $67.82 | $25.61 | BUY | +164.8% | |
| $66.79 | $25.83 | BUY | +158.6% | |
| $65.10 | $26.49 | BUY | +145.8% | |
| $65.10 | $25.63 | BUY | +154.0% | |
| $65.75 | $24.91 | BUY | +164.0% | |
| $65.75 | $27.02 | BUY | +143.4% | |
| $64.72 | $32.09 | BUY | +101.7% |
Frequently Asked Questions
What is the RARE stock price prediction for 2030?
Looking ahead to 2030, our model projects RARE could trade at an average price of $214.33, with a potential range between $160.75 and $267.92. This represents a potential 707.9% return from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.
Is RARE a buy, sell, or hold right now?
24/7 Wall St. currently rates RARE as a BUY. Strong upside (+155.6%) Among Wall Street analysts, 17 rate it Buy, 2 rate it Hold, and 0 rate it Sell.
What is the RARE stock price target in an optimistic scenario?
In our optimistic scenario for RARE, the stock could reach $72.85 over the next 12 months, representing a 174.6% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.
What is the downside risk for RARE stock?
Our conservative scenario for RARE projects a price of $52.41 over the next 12 months (97.5% from current levels), suggesting relatively limited downside if headwinds materialize. No forecast is a guarantee. Position sizing and time horizon still matter.
Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →